NCT02047487Unknown不适用
Docetaxel (T), Cisplatin (P) After Induction Chemotherapy With and Without Cisplatin (P) Concurrent Radiotherapy (X) Plus Bevacizumab (B) Phase II Clinical Study
Chinese PLA General Hospital2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2013年5月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 120
- 试验地点
- 2
- 主要终点
- ORR
研究概览
简要总结
This is a randomized, open controlled multicenter phase II clinical study. The SPSS statistical software estimation of sample size, selection of the initial treatment of locally advanced head and neck squamous cell carcinoma in 120 patients, such as to achieve the desired results, considering expanding the clinical, according to the proportion of 1:1 were randomly divided into two groups, all patients were taken, docetaxel + cisplatin 2 cycles of induction chemotherapy 、Concurrent chemoradiotherapy（tomotherapy+cisplatin）, The experimental group was added with AVASTIN.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men and women are not limited, requirements of ECOG0-2, age 18-70 years old, pathological stage III (NCCN2012), had not received radiotherapy and chemotherapy, expected to survive more than 3 months, the routine testing, were in the normal range, signed the informed consent
排除标准
- •Do not meet the above criteria; allergic to docetaxel and AVASTIN, or metabolic disorders; associated with gastrointestinal bleeding, perforation and other serious diseases; severe liver disease, kidney disease, respiratory disease or unable to control diabetes, hypertension and other chronic disease; heart disease clinical symptoms; there is peripheral nervous system disorders or have obvious mental disorder and disorders of the central nervous system; active phase >CTCAE2 clinical severe infection; a history of organ transplantation (including bone marrow transplantation of autologous peripheral stem cell transplantation); pregnant, lactating women, women of childbearing age and spouse refused to take effective means of contraception contraception; no legal capacity, continue to influence medical or ethical reasons for who
结局指标
主要结局
ORR
时间窗: three month after ratiotherapy
次要结局
未报告次要终点
研究者
zhifei zhao
resident physician
Chinese PLA General Hospital
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNNSquamous Cell Carcinoma of the Hypopharynx Stage IIISquamous Cell Carcinoma of the Hypopharynx Stage IVSquamous Cell Carcinoma of the Larynx Stage IIISquamous Cell Carcinoma of the Larynx Stage IVSquamous Cell Carcinoma of the Oropharynx Stage IIISquamous Cell Carcinoma of the Oropharynx Stage IVSquamous Cell Carcinoma of the Oral Cavity Stage IIISquamous Cell Carcinoma of the Oral Cavity Stage IVNCT01884259Arbeitsgemeinschaft medikamentoese Tumortherapie100
终止
2 期
Study of Induction Docetaxel, Cisplatin and 5-FluorouracilSquamous Cell CarcinomaOral CancerNCT00400205Emory University14
撤回
1 期
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)Head and Neck Squamous Cell Carcinoma (HNSCC)NCT03114280Centre Antoine Lacassagne
招募中
3 期
Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal CarcinomaLocally Advanced Nasopharyngeal CarcinomaNCT03015727Zhejiang Cancer Hospital440
Unknown
2 期
the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal CancerLocally Advanced Head and Neck Squamous Cell CarcinomaNCT03196869Guiyang Medical University128